STAAR Surgical's China Recovery Is Real. The Question Is Whether It Lasts.

The China reset

The $90 million preliminary figure looks dramatic against the year-ago quarter, but the comparison is misleading without context. In the first quarter of 2025, STAAR shipped minimal quantities of its EVO Implantable Collamer Lenses to China while distributors worked through excess inventory that had accumulated during a period of macroeconomic disruption. That deliberate pause cratered Q1 2025 revenue to $42.6 million and produced a net margin of negative 127.3 percent.

The rebound, then, is partly a function of the base effect: STAAR is comparing against a quarter in which it essentially stopped shipping product to its most important market. The company noted that distributor inventory "appears to be within the Company's targeted range to appropriately service the refractive market" as of the end of Q1 2026. That is a meaningful milestone. For much of 2024 and 2025, STAAR lacked complete visibility into downstream inventory levels, a problem the company acknowledged in its March 2026 shareholder letter.

China accounted for "the majority of the increase in net sales," according to Interim Co-CEO and CFO Deborah Andrews. The Americas contributed continued double-digit growth, but the scale of the China contribution makes clear that the headline number lives or dies on that single market.

The earnings picture is murkier

Revenue recovery is only half the story. STAAR's profitability has been volatile in a way that complicates the bull case:

The Q3 2025 figure (9.4 percent net margin) was the lone profitable quarter in the last four reporting periods. Q4 2025 posted a net margin of negative 31.7 percent despite gross margins of 73.4 percent, suggesting that operating expenses remain elevated relative to revenue.

Andrews said the company expects "a meaningful improvement in adjusted EBITDA" for Q1 2026, citing higher sales combined with a "significantly improved cost structure." The cost reductions are real: STAAR's shareholder letter detailed significant headcount and marketing expense cuts implemented throughout 2025, including a shift away from expensive direct-to-consumer campaigns in the United States that "didn't deliver in the way that we expected."

But the company continues to provide no forward revenue or earnings guidance, a notable omission for a stock trading at negative earnings. Wall Street's consensus estimate for Q1 2026 called for revenue of approximately $70 million and EPS of $0.12. The preliminary sales figure handily clears the revenue bar, but profitability remains unconfirmed until the full 10-Q filing in early May.

The analyst landscape

The Canaccord upgrade is the most significant rating change in months, but the broader analyst consensus remains cautious. Of 14 analysts covering STAA, 11 hold a Hold rating, two rate it a Buy, and one rates it a Sell. Morgan Stanley initiated coverage in January with an Underweight rating and a $13 price target. Wells Fargo cut its target from $30.75 to $16 in March.

The median price target of $22 now sits below the current trading price of $25.16, which means the stock has run past where most analysts think it should be. That gap will either close through target revisions (as Canaccord's move to $27 suggests) or through a pullback if the full Q1 results disappoint on margins.

Structural risks remain

To be sure, the preliminary sales figure validates the thesis that China's refractive surgery market is recovering and that STAAR's inventory channel reset is working. The February 2026 FDA decision to expand the EVO and EVO+ age indication to patients aged 21 to 60 (from the previous 21 to 45 range) widens the addressable market in the United States and could provide a secondary growth lever.

But the company's own press release flagged that net sales in the Middle East and parts of EMEA and APAC were "negatively affected by significant geopolitical and macroeconomic challenges," resulting in declining sales in those regions. STAAR cautioned that "sales growth could continue to be adversely affected if these conditions persist, and that macroeconomic challenges could spread to other regions."

The leadership situation adds another layer of uncertainty. STAAR is operating under an interim co-CEO structure after shareholders rejected a proposed merger with Alcon in January 2026. The shareholder letter acknowledged that the Alcon process "created temporary uncertainty across parts of our distribution network and diverted management focus." The company has not announced a permanent CEO search timeline.

Then there is the concentration risk. STAAR's reliance on a single distributor in China for the majority of its revenue creates a fragility that no amount of product innovation can fully offset. The 2025 inventory debacle demonstrated how quickly that dependency can crater results.

What comes next

The full Q1 2026 earnings report, expected in early May, will determine whether the revenue recovery translates into the profitability improvement Andrews promised. Consensus estimates call for EPS of $0.12 on revenue of approximately $70 million. The revenue figure is likely to be revised sharply upward; the earnings figure is the one to watch.

STAAR's stock now trades 85 percent below its September 2021 all-time high of $163.08. The company that once commanded a $7 billion market capitalization on hypergrowth expectations is now a $1.2 billion turnaround story. The preliminary Q1 number is the strongest evidence yet that the turnaround is underway. Only time will tell whether it holds.